Last reviewed · How we verify
Placebo to etoricoxib
Placebo to etoricoxib is a NSAID Small molecule drug developed by Organon and Co. It is currently in Phase 3 development for Osteoarthritis, Rheumatoid arthritis.
Etoricoxib is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits COX-2, reducing prostaglandin synthesis and inflammation.
Etoricoxib is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits COX-2, reducing prostaglandin synthesis and inflammation. Used for Osteoarthritis, Rheumatoid arthritis.
At a glance
| Generic name | Placebo to etoricoxib |
|---|---|
| Sponsor | Organon and Co |
| Drug class | NSAID |
| Target | COX-2 |
| Modality | Small molecule |
| Therapeutic area | Rheumatology |
| Phase | Phase 3 |
Mechanism of action
This selective inhibition of COX-2 results in reduced inflammation and pain, making it effective for treating conditions such as osteoarthritis and rheumatoid arthritis. Etoricoxib's mechanism of action is distinct from traditional NSAIDs, which inhibit both COX-1 and COX-2 enzymes.
Approved indications
- Osteoarthritis
- Rheumatoid arthritis
Common side effects
- Gastrointestinal upset
- Headache
- Dizziness
Key clinical trials
- An Investigational Drug Study in the Treatment of Primary Dysmenorrhea (0663-064) (PHASE3)
- A Study to Assess the Safety and Efficacy of an Investigational Drug in Patients With Osteoarthritis (0663-071)(COMPLETED) (PHASE3)
- A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-076)(COMPLETED) (PHASE3)
- An Investigational Drug in Patients With Osteoarthritis (0663-073) (PHASE3)
- A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-077)(COMPLETED) (PHASE3)
- The Single Dose Pharmacokinetics of Two and Proof of Efficacy of One New Etoricoxib Gel Formulation in Participants With Osteoarthritis (MK-0663-168) (PHASE1, PHASE2)
- A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108) (PHASE3)
- A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to etoricoxib CI brief — competitive landscape report
- Placebo to etoricoxib updates RSS · CI watch RSS
- Organon and Co portfolio CI
Frequently asked questions about Placebo to etoricoxib
What is Placebo to etoricoxib?
How does Placebo to etoricoxib work?
What is Placebo to etoricoxib used for?
Who makes Placebo to etoricoxib?
What drug class is Placebo to etoricoxib in?
What development phase is Placebo to etoricoxib in?
What are the side effects of Placebo to etoricoxib?
What does Placebo to etoricoxib target?
Related
- Drug class: All NSAID drugs
- Target: All drugs targeting COX-2
- Manufacturer: Organon and Co — full pipeline
- Therapeutic area: All drugs in Rheumatology
- Indication: Drugs for Osteoarthritis
- Indication: Drugs for Rheumatoid arthritis